CN117229409B - Anti-phencyclidine antibody, reagent for detecting phencyclidine and kit - Google Patents

Anti-phencyclidine antibody, reagent for detecting phencyclidine and kit Download PDF

Info

Publication number
CN117229409B
CN117229409B CN202210638701.2A CN202210638701A CN117229409B CN 117229409 B CN117229409 B CN 117229409B CN 202210638701 A CN202210638701 A CN 202210638701A CN 117229409 B CN117229409 B CN 117229409B
Authority
CN
China
Prior art keywords
antibody
ser
antigen
binding fragment
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210638701.2A
Other languages
Chinese (zh)
Other versions
CN117229409A (en
Inventor
孟媛
钟冬梅
唐丽娜
周全兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dongguan Pengzhi Biotechnology Co Ltd
Original Assignee
Dongguan Pengzhi Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongguan Pengzhi Biotechnology Co Ltd filed Critical Dongguan Pengzhi Biotechnology Co Ltd
Priority to CN202210638701.2A priority Critical patent/CN117229409B/en
Publication of CN117229409A publication Critical patent/CN117229409A/en
Application granted granted Critical
Publication of CN117229409B publication Critical patent/CN117229409B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

The invention discloses an anti-phencyclidine antibody, a phencyclidine detection reagent and a phencyclidine detection kit, and relates to the technical field of antibodies. The anti-phencyclidine antibodies disclosed herein comprise a heavy chain complementarity determining region and a light chain complementarity determining region. The antibody provides an important raw material source for detecting phencyclidine, and has improved affinity and activity.

Description

Anti-phencyclidine antibody, reagent for detecting phencyclidine and kit
Technical Field
The invention relates to the technical field of antibodies, in particular to an anti-phencyclidine antibody, a phencyclidine detection reagent and a phencyclidine detection kit.
Background
Phencyclidine (PHENCYCLINDINE, PCP), commonly known as "Angel powder", trade name SemyLan, chemical name [1- (1-phenylcyclohexyl) piperidine, molecular formula C17H25N, molecular weight 243.2. The PCP pure product is white crystal powder, and has no smell; usually in the form of hydrochloride, is easily dissolved in water, ethanol and chloroform, and is often prepared into powder, and also in the form of tablets, capsules, injection and the like. Most PCPs are yellow to brown in color due to the incorporation of other additives. PCP synthesis was originally used as an anesthetic in the 50 s of the 20 th century. It was soon found that hallucinations occur during anesthesia, PCP is known by more than 50 names in the drug market, such as: angel powder, crystals, super glass, rocket fuel, etc., are often mistaken for hemp, LSD, etc. Because of its simple manufacture and low cost, a vendor often mixes PCP with other drugs and even venues like other drugs.
After PCP is administered, it can be absorbed in vivo via various routes, distributed on various parts of the whole body, and has excitation, inhibition, illusion and pain relieving effects on central nervous system, and can generate illusion during anesthesia, which is called as illusion agent. The mechanism of action is to block chloride and sodium channels on nerve cells, which are activated by the neurotransmitter sodium glutamate, which opens ion channels through the activation of its specific receptor N-methyl D-aspartate (NMDA) receptor, and PCP can selectively block NMDA receptors while also affecting the function of the dopamine transmitter system.
The difference between the therapeutic amount of PCP and the toxic amount is small. The dosage of the medicine is 10mg for oral administration, 0.2mg/kg body weight for intravenous injection, 0.007-0.024 g/mL of poisoning blood concentration and l-5 g/mL of death blood concentration. The PCP is easy to generate tolerance, and can make a human body feel euphoric after being taken once, so that the sensitivity to external stimulus is enhanced, the emotion is improved, and the typical euphoric can last for 4-5 hours. Thus giving a strong craving for it. After long-term use, anxiety, major depression and the like appear, and medicines remained in the body repeatedly act after stopping taking, some symptoms still appear, and the symptoms are expressed as follows: respiratory depression, hallucinations, agitation, tension, movement disorders, vomiting, convulsions, rashes, nystagmus, increased blood pressure, increased salivation, hyperpyrexia, sweating, repeated movements, etc., and severe cases are coma, convulsions and even death. Thus, PCP is considered one of the most harmful drugs at present.
In the work of drug inhibition, in order to study and infer the drug absorption history of drug-takers and monitor the high-risk group and drug-taker group, the hair and urine samples of the drug-takers, especially the hair poisoning components, need to be detected, and the length of the drug absorption time can be inferred. In practice, in vivo drug detection is usually performed by urine and blood, and hair is rarely detected. Since the drug is metabolized and excreted from urine quickly in one or two days, rapid confirmation of PCP in urine will increase efficiency for detoxification work. The current detection methods for PCP mainly include chromatography, enzyme-linked immunosorbent assay (ELISA), and colloidal gold method.
The use of chromatography in clinical applications is further under investigation due to its long time consuming and expensive nature. The immunoassay method is simple and rapid, and is a hot spot for research. Thus, there is a strong need in the art for antibodies that bind and detect PCP efficiently and specifically, and the present invention discloses a monoclonal antibody that specifically recognizes PCP, and can be used for the recognition, detection, etc. of PCP.
Disclosure of Invention
The application provides a phencyclidine antibody with improved affinity and activity, which is used for detecting phencyclidine, and provides an important raw material source for detecting phencyclidine.
In order to achieve the above object, according to one aspect of the present invention, there is provided an antibody or a functional fragment thereof comprising HCDR1, HCDR2, HCDR3 having amino acid sequences shown in SEQ ID NO. 1 to SEQ ID NO. 3, and LCDR1, LCDR2, LCDR3 having amino acid sequences shown in SEQ ID NO. 4 to SEQ ID NO. 6.
In order to achieve the above object, according to a second aspect of the present invention, there is provided an anti-phencyclidine antibody or a functional fragment thereof, which comprises a heavy chain variable region comprising the sequence structure of HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4 and/or a light chain variable region comprising the sequence structure of LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4, wherein the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 are the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 described above.
In order to achieve the above object, according to a third aspect of the present invention, there is provided an anti-phencyclidine antibody comprising a heavy chain comprising the heavy chain variable region described above and/or a light chain comprising the light chain variable region described above.
In order to achieve the above object, according to a fourth aspect of the present invention, there is provided an antibody conjugate comprising the above antibody or a functional fragment thereof.
In order to achieve the above object, according to a fifth aspect of the present invention, there is provided a reagent or kit for detecting phencyclidine, the reagent or kit comprising the above antibody or a functional fragment thereof or the above antibody conjugate.
In order to achieve the above object, the present invention also provides a vector, a cell and a method for preparing the above antibody or a functional fragment thereof.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings that are needed in the embodiments will be briefly described below, it being understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and other related drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 shows the results of reducing SDS-PAGE of Anti-PCP 15C9mut1 to Anti-PCP 15C9mut3 in order from left to right, with one repeat for each antibody.
Detailed Description
The invention provides an antibody or a functional fragment thereof, which comprises HCDR1, HCDR2 and HCDR3 with amino acid sequences shown in SEQ ID NO.1 to SEQ ID NO. 3, and LCDR1, LCDR2 and LCDR3 with amino acid sequences shown in SEQ ID NO. 4 to SEQ ID NO. 6. The antibodies have improved affinity and activity.
In the present invention, the term "antibody" is used in the broadest sense and may include full length monoclonal antibodies, bispecific or multispecific antibodies, and chimeric antibodies so long as they exhibit the desired biological activity.
In the present invention, the terms "complementarity determining regions", "CDRs" or "CDRs" refer to the highly variable regions of the heavy and light chains of immunoglobulins, and refer to regions comprising one or more or even all of the major amino acid residues contributing to the binding affinity of an antibody or antigen binding fragment to the antigen or epitope it recognizes. In a specific embodiment of the invention, CDRs refer to the highly variable regions of the heavy and light chains of the antibody.
In the present invention, the heavy chain complementarity determining region is represented by HCDR, which includes HCDR1, HCDR2 and HCDR3; the light chain complementarity determining regions are denoted by LCDR and include LCDR1, LCDR2 and LCDR3. CDR labeling methods commonly used in the art include: the Kabat numbering scheme, the IMGT numbering scheme, the Chothia and Lesk numbering schemes, 1997 Lefranc et al, all protein sequences of the immunoglobulin superfamily. The invention adopts Kabat annotation standard to mark CDR regions, but other methods to mark CDR regions also belong to the protection scope of the invention.
In the present invention, a "framework region" or "FR" region includes a heavy chain framework region and a light chain framework region, and refers to regions other than CDRs in an antibody heavy chain variable region and a light chain variable region; wherein the heavy chain framework regions can be further subdivided into contiguous regions separated by CDRs comprising HFR1, HFR2, HFR3 and HFR4 framework regions; the light chain framework regions may be further subdivided into contiguous regions separated by CDRs comprising LFR1, LFR2, LFR3 and LFR4 framework regions.
In the present invention, the heavy chain variable region is obtained by connecting the following numbered CDRs with FRs in the following combination arrangement: HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4; the light chain variable region is obtained by ligating the following numbered CDRs with the FR in the following combination arrangement: LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4.
In alternative embodiments, the antibody or functional fragment thereof further comprises HFR1, HFR2, HFR3, HFR4 having amino acid sequences shown in SEQ ID NO. 7 through SEQ ID NO. 10, and LFR1, LFR2, LFR3 and LFR4 having amino acid sequences shown in SEQ ID NO. 11 through SEQ ID NO. 14.
In other embodiments, each of the framework amino acid sequences of the antibodies or functional fragments thereof provided herein may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology to the corresponding framework region (SEQ ID NO:7, 8, 9, 10, 11, 12, 13 or 14) described above.
In an alternative embodiment, the antibody or functional fragment thereof binds phencyclidine with an affinity of KD.ltoreq.10 10 -9 M.
In an alternative embodiment, the antibody or functional fragment thereof binds to phencyclidine with an affinity of KD.ltoreq.4.81X 10 -10 M.
In an alternative embodiment, the antibody or functional fragment thereof binds phencyclidine with an affinity of KD.ltoreq.10 10 -10M、KD≤10-11 M.
In an alternative embodiment, the antibody or functional fragment thereof binds to phencyclidine with an affinity of KD.ltoreq.1.51X10 -10 M.
In an alternative embodiment, the antibody or functional fragment thereof binds to phencyclidine with an affinity of KD.ltoreq.5.93X1 -10 M.
In an alternative embodiment, LFR1 of said antibody or functional fragment thereof is shown as SEQ ID NO. 15.
In an alternative embodiment, LFR2 of said antibody or functional fragment thereof is shown as SEQ ID NO. 16.
In another aspect, embodiments of the present invention provide an anti-phencyclidine antibody or a functional fragment thereof, the antibody or the functional fragment thereof comprises a heavy chain variable region and/or a light chain variable region, the heavy chain variable region comprises a sequence structure of HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4, the light chain variable region comprises a sequence structure of LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4, and the amino acid sequence of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 is the amino acid sequence of HCDR1, HCDR2, HCDR3, LCDR1, LCDR3, HFR1, HFR2, HFR4, LFR1, HFR2, LFR3, LFR4 is the amino acid sequence of HFR1, HFR2, HFR3, LFR4, LFR2, LFR 4.
In an alternative embodiment, the heavy chain variable region amino acid sequence is set forth in SEQ ID NO. 19.
In an alternative embodiment, the light chain variable region amino acid sequence is set forth in SEQ ID NOS.20 to 23.
In alternative embodiments, the antibody further comprises a constant region.
In alternative embodiments, the constant region comprises a heavy chain constant region and/or a light chain constant region.
In alternative embodiments, the heavy chain constant region is selected from the group consisting of an IgG1, igG2, igG3, igG4, igA, igM, igE, or IgD heavy chain constant region, and the light chain constant region is selected from the group consisting of kappa-type or lambda-type light chain constant regions.
In alternative embodiments, the constant region is of a species derived from a cow, horse, cow, pig, sheep, rat, mouse, dog, cat, rabbit, donkey, deer, mink, chicken, duck, goose, turkey, chicken, or human.
In an alternative embodiment, the constant region is of ovine species.
In an alternative embodiment, the constant region is of a species origin from goat.
In an alternative embodiment, the heavy chain constant region sequence (CH) is shown in SEQ ID NO. 17 and the light chain constant region (CL) sequence is shown in SEQ ID NO. 18.
In other embodiments, the constant region sequence may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology to the above-described constant region (SEQ ID NO:17 or 18).
In alternative embodiments, the functional fragment is selected from any one of F (ab ') 2, fab', fab, fv, and scFv of the antibody.
The functional fragments of the above antibodies generally have the same binding specificity as the antibody from which they were derived. It will be readily appreciated by those skilled in the art from the disclosure herein that functional fragments of the above antibodies may be obtained by methods such as enzymatic digestion (including pepsin or papain) and/or by methods of chemical reduction cleavage of disulfide bonds. The above functional fragments are readily available to those skilled in the art based on the disclosure of the structure of the intact antibodies.
Functional fragments of the above antibodies may also be synthesized by recombinant genetic techniques also known to those skilled in the art or by, for example, automated peptide synthesizers such as those sold by Applied BioSystems and the like.
In another aspect, the invention provides an antibody against phencyclidine comprising a heavy chain and/or a light chain, said heavy chain comprising a heavy chain variable region as described above and a heavy chain constant region as described above; the light chain comprises the light chain variable region described above and the light chain constant region described above.
In an alternative embodiment, the amino acid sequence of the heavy chain is shown in SEQ ID NO. 24.
In an alternative embodiment, the amino acid sequence of the light chain is as shown in any one of SEQ ID NOs 25 to 28.
In another aspect, the invention provides an antibody conjugate comprising an antibody or functional fragment thereof as described above.
In an alternative embodiment, the antibody or functional fragment thereof in the above antibody conjugate is labeled with a label.
In an alternative embodiment, the above-mentioned marker refers to a substance having a property such as luminescence, color development, radioactivity, etc., which can be directly observed by naked eyes or detected by an instrument, by which qualitative or quantitative detection of the corresponding target can be achieved.
In alternative embodiments, the labels include, but are not limited to, fluorescent dyes, enzymes, radioisotopes, chemiluminescent reagents, and nanoparticle-based labels.
In the actual use process, a person skilled in the art can select a suitable marker according to the detection conditions or actual needs, and no matter what marker is used, the marker belongs to the protection scope of the invention.
In alternative embodiments, the fluorescent dyes include, but are not limited to, fluorescein-based dyes and derivatives thereof (including, but not limited to, fluorescein Isothiocyanate (FITC) hydroxy-light (FAM), tetrachlorolight (TET), and the like, or analogs thereof), rhodamine-based dyes and derivatives thereof (including, but not limited to, red Rhodamine (RBITC), tetramethyl rhodamine (TAMRA), rhodamine B (TRITC), and the like, or analogs thereof), cy-based dyes and derivatives thereof (including, but not limited to, cy2, cy3B, cy3.5, cy5, cy5.5, cy3, and the like, or analogs thereof), alexa-based dyes and derivatives thereof (including, but not limited to, alexa fluor350, 405, 430, 488, 532, 546, 555, 568, 594, 610, 33, 647, 680, 700, 750, and the like, or analogs thereof), and protein-based dyes and derivatives thereof (including, but not limited to, for example, phycoerythrin (PE), phycocyanin (PC), allophycocyanin (APC), polyazosin (preCP), and the like).
In alternative embodiments, the enzymes include, but are not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and glucose 6-phosphate deoxygenase.
In alternative embodiments, the radioisotope includes, but is not limited to 212Bi、131I、111In、90Y、186Re、211At、125I、188Re、153Sm、213Bi、32P、94mTc、99mTc、203Pb、67Ga、68Ga、43Sc、47Sc、110mIn、97Ru、62Cu、64Cu、67Cu、68Cu、86Y、88Y、121Sn、161Tb、166Ho、105Rh、177Lu、172Lu and 18 F.
In alternative embodiments, the chemiluminescent reagents include, but are not limited to, luminol and its derivatives, lucigenin, crustacean fluorescein and its derivatives, ruthenium bipyridine and its derivatives, acridinium esters and its derivatives, dioxane and its derivatives, lomustine and its derivatives, and peroxyoxalate and its derivatives.
In alternative embodiments, the nanoparticle-based labels include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles.
In alternative embodiments, the colloids include, but are not limited to, colloidal metals, disperse dyes, dye-labeled microspheres, and latex.
In alternative embodiments, the colloidal metals include, but are not limited to, colloidal gold, colloidal silver, and colloidal selenium.
In an alternative embodiment, the antibody or functional fragment thereof in the above antibody conjugate is coated onto a solid phase.
In alternative embodiments, the solid phase is selected from the group consisting of microspheres, plates, and membranes.
In alternative embodiments, the solid phase includes, but is not limited to, magnetic microspheres, plastic microparticles, microplates, glass, capillaries, nylon, and nitrocellulose membranes.
In an alternative embodiment, the solid phase is a nitrocellulose membrane.
In another aspect, the invention provides a reagent or kit for detecting phencyclidine, the reagent or kit comprising the antibody or functional fragment thereof or the antibody conjugate.
In another aspect, the invention provides the use of an antibody as described above or a functional fragment thereof, an antibody conjugate, or a reagent or kit as described above in the detection of phencyclidine.
In another aspect, the invention provides a nucleic acid molecule encoding an antibody or functional fragment thereof as described above.
In another aspect, the invention provides a vector comprising the nucleic acid molecule described above.
In another aspect, the invention provides a cell comprising the vector described above.
In another aspect, the invention provides a method of making an antibody or functional fragment thereof comprising: the cells as described above were cultured.
On the basis of the present invention, which discloses the amino acid sequence of an antibody or a functional fragment thereof, it is easy for a person skilled in the art to prepare the antibody or the functional fragment thereof by genetic engineering techniques or other techniques (chemical synthesis, recombinant expression), for example, by separating and purifying the antibody or the functional fragment thereof from a culture product of recombinant cells capable of recombinantly expressing the antibody or the functional fragment thereof according to any one of the above, and on the basis of this, it is within the scope of the present invention to prepare the antibody or the functional fragment thereof by any technique.
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions of the embodiments of the present invention will be clearly and completely described below. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of formulations or unit doses herein, some methods and materials are now described. Unless otherwise indicated, techniques employed or contemplated herein are standard methods. The materials, methods, and examples are illustrative only and not intended to be limiting.
Unless otherwise indicated, practice of the present invention will employ conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry and immunology, which are within the ability of a person skilled in the art. This technique is well explained in the literature, as is the case for molecular cloning: laboratory Manual (Molecular Cloning: A Laboratory Manual), second edition (Sambrook et al, 1989); oligonucleotide Synthesis (Oligonucleotide Synthesis) (M.J.Gait, eds., 1984); animal cell Culture (ANIMAL CELL Culture) (r.i. freshney, 1987); methods of enzymology (Methods in Enzymology) (academic Press Co., ltd. (ACADEMIC PRESS, inc.)), experimental immunology handbook (Handbook of Experimental Immunology) (D.M.Weir and C.C. Blackwell, inc.), gene transfer Vectors for mammalian cells (GENE TRANSFER vector for MAMMALIAN CELLS) (J.M.Miller and M.P.Calos, inc., 1987), methods of contemporary molecular biology (Current Protocols in Molecular Biology) (F.M.Ausubel et al, 1987), polymerase chain reaction (PCR: the Polymerase Chain Reaction) (Mullis et al, 1994), and methods of contemporary immunology (Current Protocols in Immunology) (J.E.Coligan et al, 1991), each of which are expressly incorporated herein by reference.
The features and capabilities of the present invention are described in further detail below in connection with the examples.
EXAMPLE 1 preparation of Anti-PCP-15C9 monoclonal antibody
Restriction enzymes, PRIME STAR DNA polymerase in this example were purchased from Takara. MagExtractor-RNA extraction kit was purchased from TOYOBO company. BD SMART TM RACE cDNA Amplification Kit kit was purchased from Takara. pMD-18T vector was purchased from Takara. Plasmid extraction kits were purchased from Tiangen. Primer synthesis and gene sequencing were accomplished by Invitrogen corporation.
1 Construction of recombinant plasmid
(1) Antibody Gene production
MRNA is extracted from hybridoma cell strain secreting monoclonal antibody of phencyclidine, DNA product is obtained through RT-PCR method, the product is inserted into pMD-18T vector after adding A reaction by rTaq DNA polymerase, and is transformed into DH5 alpha competent cells, HEAVY CHAIN and LIGHT CHAIN gene clones are respectively taken after colony growth, and each 4 clones are sent to gene sequencing company for sequencing.
(2) Sequence analysis of Anti-PCP-15C9 antibody variable region Gene
The gene sequence obtained by sequencing is placed in an IMGT antibody database for analysis, and VNTI 11.5.5 software is used for analysis to determine that the amplified genes of the heavy chain primer pair and the light chain primer pair are correct, wherein in the LIGHT CHAIN amplified gene fragment, the VL gene sequence is 336bp, and the front side of the VL gene sequence is 57bp leader peptide sequence; the VH gene sequence in the gene fragment amplified by HEAVY CHAIN primer pair is 363bp, belonging to VH1 gene family, and the front of the gene fragment has 57bp leader peptide sequence.
(3) Construction of recombinant antibody expression plasmids
pcDNATM3.4Vector is a constructed eukaryotic expression vector of the recombinant antibody, and the expression vector is introduced with HindIII, bamHI, ecoRI and other polyclonal enzyme cutting sites and named pcDNA3.4A expression vector, and is hereinafter abbreviated as 3.4A expression vector; according to the result of the gene sequencing of the antibody variable region in pMD-18T, VL and VH gene specific primers of the Anti-PCT 15C9 antibody are designed, the two ends of the VL and VH gene specific primers are respectively provided with HindIII, ecoRI digestion sites and protective bases, and a LIGHT CHAIN gene fragment of 0.74KB and a HEAVY CHAIN gene fragment of 1.42KB are amplified by a PCR amplification method.
The HEAVY CHAIN and LIGHT CHAIN gene fragments are respectively cut by HindIII/EcoRI double enzyme, the 3.4A vector is cut by HindIII/EcoRI double enzyme, the HEAVY CHAIN gene and LIGHT CHAIN gene after the fragments and the vector are purified and recovered are respectively connected with the 3.4A expression vector, and recombinant expression plasmids of HEAVY CHAIN and LIGHT CHAIN are respectively obtained.
2 Stable cell line selection
(1) Recombinant antibody expression plasmid transient transfection CHO cells, determination of expression plasmid activity
The plasmid was diluted to 40ug/100ul with ultrapure water, CHO cells were adjusted to 1.43X107 cells/ml in centrifuge tubes, 100ul of plasmid was mixed with 700ul of cells, transferred to an electrorotating cup, electrorotated, sampled and counted on days 3, 5, 7, and collected on day 7.
The coating solution (NaHCO 3 as the main component) was diluted to 3ug/ml of PCP-BSA (Handersen, cat. HDS-A4040) 100uL per well overnight at 4 ℃; the next day, washing with washing liquid for 2 times, and drying; blocking solution (20% BSA+80% PBS) was added and dried at 37℃for 1h in 120uL per well; adding diluted cell supernatant, 100 uL/well, 37℃for 30min (1 h for part of supernatant); washing with washing liquid for 5 times, and drying; adding sheep anti-mouse IGG-HRP, 100uL per hole, 37 ℃ for 30min; washing with washing liquid for 5 times, and drying; adding a developing solution A (50 uL/hole) and a developing solution B (50 uL/hole) for 10min; adding a stop solution, 50 uL/well; OD was read on the microplate reader at 450nm (reference 630 nm). The results showed that the reaction OD after 1000-fold dilution of the cell supernatant was still greater than 1.0, and that the reaction OD without cell supernatant was less than 0.1, indicating that the antibodies produced after transient transformation of the plasmid were active against PCP-BSA (Handersen, cat. HDS-A4040).
The reactivity of the cell supernatant with BSA was examined by the same method as described above, and the results showed that the cell supernatant was diluted 1000-fold and the OD was less than 0.1, and that the cell supernatant was not added and the OD was less than 0.1, indicating that the antibody produced after transient transformation of the plasmid was inactive against BSA, further demonstrating that the cell supernatant was active against PCP.
(2) Linearization of recombinant antibody expression plasmids
The following reagents were prepared: buffer 50 mu L, DNA mu g/tube, puv I enzyme 10 mu L, sterile water to 500 mu L, water bath at 37 ℃ for enzyme digestion overnight; firstly, extracting with equal volume of phenol/chloroform/isoamyl alcohol (lower layer) 25:24:1, and then sequentially extracting with chloroform (water phase); precipitating 0.1 times volume (water phase) of 3M sodium acetate and 2 times volume of ethanol on ice, rinsing the precipitate with 70% ethanol, removing organic solvent, completely volatilizing ethanol, re-thawing with appropriate amount of sterilized water, and measuring concentration.
(3) Stable transfection of recombinant antibody expression plasmid and pressure screening of stable cell strain
Diluting the plasmid to 40ug/100ul with ultrapure water, regulating CHO cells to 1.43X10 7 cells/ml in a centrifuge tube, mixing 100 mu L of plasmid with 700 mu L of cells, transferring into an electrorotating cup, electrorotating, and counting the next day; 25umol/L MSX 96-well pressure culture for about 25 days.
Observing the clone holes with the cells under a microscope, and recording the confluency; taking culture supernatant, and carrying out sample feeding detection; selecting cell strains with high antibody concentration and relative concentration, turning 24 holes, and turning 6 holes about 3 days; seed preservation batch culture is carried out after 3 days, cell density is adjusted to be 0.5X10 6 cells/ml, batch culture is carried out by 2.2ml, and seed preservation is carried out by 2ml, wherein the cell density is 0.3X10 6 cells/ml; and (3) carrying out sample feeding detection on the culture supernatant of the 6-hole batch culture for 7 days, and selecting cell strains with smaller antibody concentration and smaller cell diameter to transfer TPP for seed preservation and passage.
3 Recombinant antibody production
(1) Cell expansion culture
After cell recovery, the cells were first cultured in 125ml shake flasks with an inoculation volume of 30ml and a medium of 100% dynamis and placed in a shaker at a speed of 120r/min at 37℃and with 8% carbon dioxide. Culturing for 72h, inoculating and expanding culture at 50 ten thousand cells/ml inoculating density, and calculating the expanding culture volume according to production requirements, wherein the culture medium is 100% Dynamis culture medium. After that, the culture was spread every 72 hours. When the cell quantity meets the production requirement, the inoculation density is strictly controlled to be about 50 ten thousand cells/ml for production.
(2) Shake flask production and purification
Shake flask parameters: the rotating speed is 120r/min, the temperature is 37 ℃, and the carbon dioxide is 8%. Feeding: feeding is started every day when the culture is carried out in a shake flask for 72 hours, hyCloneTM Cell BoostTM Feed a is fed with 3% of the initial culture volume every day, and the feeding amount of Feed 7b is one thousandth of the initial culture volume every day until the 12 th day (feeding on 12 th day). Glucose was fed at 3g/L on day six. Samples were collected on day 13. Affinity purification was performed using a proteona affinity column. 6 μg of purified antibody was subjected to reducing SDS-PAGE, the electrophoretogram is shown in FIG. 1, and two bands were shown after reducing SDS-PAGE, 1 Mr was 50KD and the other Mr was 28KD.
Example 2 affinity and Activity optimization
The Anti-PCP-15C9 monoclonal antibody obtained in example 1 has a capacity of binding to phencyclidine, but has insufficient affinity and antibody activity, and thus the applicant has performed directed mutation on the light chain CDR and the heavy chain CDR of the antibody. The method comprises the steps of performing structural simulation of an antibody variable region, structural simulation of an antigen-antibody variable region acting complex, analysis of key amino acids of an antibody and mutation design by using a computer, designing and synthesizing a two-way primer covering a mutation site according to a mutation scheme, synthesizing primers at two ends of target DNA, performing high-fidelity PCR reaction, cloning a PCR product to a vector, and preparing the mutant antibody according to the method described in the example 1. Monoclonal antibodies with remarkably improved affinity and antibody activity are obtained through screening and are named as: anti-PCP-15C9mut1 to Anti-PCP-15C9mut3. The amino acid sequences of the respective monoclonal antibodies are shown in the following table:
TABLE 1 antibody sequences
Sample name Heavy chain sequence number Light chain sequence number
Anti-PCP-15C9mut1 SEQ ID NO:24 SEQ ID NO:27
Anti-PCP-15C9mut2 SEQ ID NO:24 SEQ ID NO:28
Anti-PCP-15C9mut3 SEQ ID NO:24 SEQ ID NO:25
Example 3 detection of Performance of antibodies
1 Affinity assay
Using the AMC sensor, the purified antibodies were diluted to 10ug/ml with PBST, and PCP-BSA (Handson, cat. HDS-A4040) was diluted gradient with PBST:
The operation flow is as follows: equilibration for 60s in buffer 1 (PBST), antibody 300s in antibody solution, incubation for 180s in buffer 2 (PBST), binding for 420s in antigen solution, dissociation for 1200s in buffer 2, sensor regeneration with 10mM pH 1.69GLY solution and buffer 3 (PBST), output data. (KD represents equilibrium dissociation constant, i.e., affinity; kon represents binding rate; kdis represents dissociation rate. PBST major component Na2 HPO4+NaCl+TW-20).
Table 2 affinity data
Sample name KD(M) kon(1/Ms) kdis(1/s)
Control 1.11E-09 4.66E+05 5.15E-04
Anti-PCP-15C9mut1 5.93E-11 4.35E+06 2.58E-04
Anti-PCP-15C9mut2 1.51E-10 4.72E+05 7.10E-05
Anti-PCP-15C9mut3 4.81E-10 4.57E+05 2.20E-04
2 Activity assay
The coating solution (NaHCO 3 as the main ingredient) was diluted to 3ug/ml of PCP-BSA (Handersen, cat. HDS-A4040) 100. Mu.L per well overnight at 4 ℃; the next day, washing with washing liquid for 2 times, and drying; blocking solution (20% BSA+80% PBS) was added, 120. Mu.l per well, 37℃for 1h, and the mixture was dried by pipetting; adding the diluted monoclonal antibody into the mixture at the temperature of 37 ℃ for 30-60 min at the concentration of 100 mu l/hole; washing with washing liquid for 5 times, and drying; adding goat anti-mouse IgG-HRP, 100 μl per well, 37deg.C, 30min; washing with washing solution (PBS) for 5 times, and drying; adding a color development solution A (50. Mu.l/hole, containing 2.1g/L citric acid, 12.25g/L citric acid, 0.07g/L acetanilide and 0.5g/L carbamide peroxide), and adding a color development solution B (50. Mu.l/hole, containing 1.05g/L citric acid, 0.186 g/LEDTA.2Na, 0.45g/L TMB and 0.2ml/L concentrated HCl) for 10min; stop solution (50. Mu.l/well, 0.75 g/EDTA.2Na and 10.2ml/L concentrated H 2SO4) was added; OD was read on the microplate reader at 450nm (reference 630 nm). The results are shown in the following table.
TABLE 3 Activity data
Sample concentration (ng/ml) 500 125 31.25 7.81 0.98 0
Control 1.734 1.448 0.605 0.158 0.033 0.006
Anti-PCP-15C9Mut1 2.062 1.695 1.003 0.429 0.084 0.064
Anti-PCP-15C9Mut2 2.076 1.902 1.293 0.804 0.288 0.071
Anti-PCP-15C9Mut3 2.106 1.929 0.799 0.179 0.042 0.010
3 Stability assessment
Placing the antibody at 4 ℃ (refrigerator), 80 ℃ (refrigerator) and 37 ℃ (incubator) for 21 days, taking 7 days, 14 days and 21 days samples for state observation, and detecting the activity of the 21 days samples, wherein the result shows that no obvious protein state change is seen for the antibody placed for 21 days under three examination conditions, and the activity is not in a descending trend along with the increase of the examination temperature, thus indicating that the antibody is stable. Table 4 below shows the results of the detection of OD after 21 days of antibody examination.
Table 4 stability data
Sample concentration (ng/ml) 500 31.25 0
4 ℃,21 Days sample 2.063 1.082 0.059
Sample at-80℃for 21 days 2.081 1.058 0.028
37 ℃ And 21 days of sample 2.019 1.003 0.047
The above description is only of the preferred embodiments of the present invention and is not intended to limit the present invention, but various modifications and variations can be made to the present invention by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
The partial amino acid sequence related to the application is as follows:
Numbering device Sequence fragments
SEQ ID NO:1 GYNMN
SEQ ID NO:2 TIDPSYGGTTYNQKFKG
SEQ ID NO:3 SGNWAFYYGL
SEQ ID NO:4 RSSQSLVHSDGNTYLE
SEQ ID NO:5 KVSNRFS
SEQ ID NO:6 FQGSHVP
SEQUENCE LISTING
<110> Dongguan City, pengzhi biotechnology Co., ltd
<120> An anti-phencyclidine antibody, a reagent for detecting phencyclidine and a kit
<130> P2022056CN01
<160> 28
<170> PatentIn version 3.5
<210> 1
<211> 5
<212> PRT
<213> Synthesis
<400> 1
Gly Tyr Asn Met Asn
1 5
<210> 2
<211> 17
<212> PRT
<213> Synthesis
<400> 2
Thr Ile Asp Pro Ser Tyr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys
1 5 10 15
Gly
<210> 3
<211> 10
<212> PRT
<213> Synthesis
<400> 3
Ser Gly Asn Trp Ala Phe Tyr Tyr Gly Leu
1 5 10
<210> 4
<211> 16
<212> PRT
<213> Synthesis
<400> 4
Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Glu
1 5 10 15
<210> 5
<211> 7
<212> PRT
<213> Synthesis
<400> 5
Lys Val Ser Asn Arg Phe Ser
1 5
<210> 6
<211> 7
<212> PRT
<213> Synthesis
<400> 6
Phe Gln Gly Ser His Val Pro
1 5
<210> 7
<211> 30
<212> PRT
<213> Synthesis
<400> 7
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr
20 25 30
<210> 8
<211> 14
<212> PRT
<213> Synthesis
<400> 8
Trp Val Lys Gln Ser Asp Gly Lys Ser Leu Glu Trp Ile Gly
1 5 10
<210> 9
<211> 32
<212> PRT
<213> Synthesis
<400> 9
Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Leu Gln
1 5 10 15
Leu Lys Ser Leu Thr Ser Gly Asp Ser Ala Val Tyr Phe Cys Ala Arg
20 25 30
<210> 10
<211> 13
<212> PRT
<213> Synthesis
<400> 10
Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
1 5 10
<210> 11
<211> 23
<212> PRT
<213> Synthesis
<400> 11
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys
20
<210> 12
<211> 15
<212> PRT
<213> Synthesis
<400> 12
Trp His Ile Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr
1 5 10 15
<210> 13
<211> 32
<212> PRT
<213> Synthesis
<400> 13
Gly Val Pro Asp Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr
1 5 10 15
Leu Glu Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
20 25 30
<210> 14
<211> 12
<212> PRT
<213> Synthesis
<400> 14
Gly Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
1 5 10
<210> 15
<211> 23
<212> PRT
<213> Synthesis
<400> 15
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Leu Ser Cys
20
<210> 16
<211> 15
<212> PRT
<213> Synthesis
<400> 16
Trp His Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr
1 5 10 15
<210> 17
<211> 323
<212> PRT
<213> Synthesis
<400> 17
Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala
1 5 10 15
Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu
50 55 60
Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gln Thr Val
65 70 75 80
Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys
85 90 95
Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro
100 105 110
Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu
115 120 125
Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser
130 135 140
Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu
145 150 155 160
Val His Thr Ala Gln Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
165 170 175
Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn
180 185 190
Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro
195 200 205
Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln
210 215 220
Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val
225 230 235 240
Ser Leu Thr Cys Met Ile Thr Asn Phe Phe Pro Glu Asp Ile Thr Val
245 250 255
Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln
260 265 270
Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn
275 280 285
Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val
290 295 300
Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His
305 310 315 320
Ser Pro Gly Lys
<210> 18
<211> 107
<212> PRT
<213> Synthesis
<400> 18
Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
1 5 10 15
Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
20 25 30
Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
35 40 45
Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
50 55 60
Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
65 70 75 80
Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
85 90 95
Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
100 105
<210> 19
<211> 121
<212> PRT
<213> Synthesis
<400> 19
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
20 25 30
Asn Met Asn Trp Val Lys Gln Ser Asp Gly Lys Ser Leu Glu Trp Ile
35 40 45
Gly Thr Ile Asp Pro Ser Tyr Gly Gly Thr Thr Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80
Leu Gln Leu Lys Ser Leu Thr Ser Gly Asp Ser Ala Val Tyr Phe Cys
85 90 95
Ala Arg Ser Gly Asn Trp Ala Phe Tyr Tyr Gly Leu Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Ser Val Thr Val Ser Ser
115 120
<210> 20
<211> 112
<212> PRT
<213> Synthesis
<400> 20
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Glu Trp His Ile Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Glu Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Gly Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
<210> 21
<211> 112
<212> PRT
<213> Synthesis
<400> 21
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Leu Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Glu Trp His Ile Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Glu Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Gly Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
<210> 22
<211> 112
<212> PRT
<213> Synthesis
<400> 22
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Glu Trp His Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Glu Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Gly Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
<210> 23
<211> 112
<212> PRT
<213> Synthesis
<400> 23
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Leu Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Glu Trp His Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Glu Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Gly Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
<210> 24
<211> 445
<212> PRT
<213> Synthesis
<400> 24
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
20 25 30
Asn Met Asn Trp Val Lys Gln Ser Asp Gly Lys Ser Leu Glu Trp Ile
35 40 45
Gly Thr Ile Asp Pro Ser Tyr Gly Gly Thr Thr Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80
Leu Gln Leu Lys Ser Leu Thr Ser Gly Asp Ser Ala Val Tyr Phe Cys
85 90 95
Ala Arg Ser Gly Asn Trp Ala Phe Tyr Tyr Gly Leu Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser
115 120 125
Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val
130 135 140
Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro
180 185 190
Ser Ser Thr Trp Pro Ser Gln Thr Val Thr Cys Asn Val Ala His Pro
195 200 205
Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly
210 215 220
Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile
225 230 235 240
Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys
245 250 255
Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln
260 265 270
Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Lys
275 280 285
Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu
290 295 300
Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg
305 310 315 320
Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
325 330 335
Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro
340 345 350
Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr
355 360 365
Asn Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln
370 375 380
Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly
385 390 395 400
Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu
405 410 415
Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn
420 425 430
His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys
435 440 445
<210> 25
<211> 219
<212> PRT
<213> Synthesis
<400> 25
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Glu Trp His Ile Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Glu Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Gly Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
115 120 125
Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
130 135 140
Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
145 150 155 160
Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
180 185 190
Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
195 200 205
Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
210 215
<210> 26
<211> 219
<212> PRT
<213> Synthesis
<400> 26
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Leu Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Glu Trp His Ile Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Glu Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Gly Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
115 120 125
Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
130 135 140
Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
145 150 155 160
Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
180 185 190
Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
195 200 205
Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
210 215
<210> 27
<211> 219
<212> PRT
<213> Synthesis
<400> 27
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Glu Trp His Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Glu Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Gly Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
115 120 125
Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
130 135 140
Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
145 150 155 160
Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
180 185 190
Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
195 200 205
Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
210 215
<210> 28
<211> 219
<212> PRT
<213> Synthesis
<400> 28
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Thr Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Leu Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Glu Trp His Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Glu Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Gly Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
115 120 125
Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
130 135 140
Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
145 150 155 160
Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
180 185 190
Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
195 200 205
Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
210 215

Claims (34)

1. An anti-phencyclidine antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3 with amino acid sequences shown in SEQ ID NO. 1-SEQ ID NO. 3, and LCDR1, LCDR2, LCDR3 with amino acid sequences shown in SEQ ID NO. 4-SEQ ID NO. 6.
2. The antibody or antigen-binding fragment thereof according to claim 1, further comprising an amino acid sequence having the amino acid sequence shown in SEQ ID No. 7 to SEQ ID No. 10 as HFR1, HFR2, HFR3, HFR4 and an amino acid sequence shown in SEQ ID No. 11 to SEQ ID No. 14 as LFR1, LFR2, LFR3 and LFR4, or an amino acid sequence having at least 80% homology with each of the sequences HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3, LFR 4.
3. The antibody or antigen-binding fragment thereof of claim 2, wherein the antibody or antigen-binding fragment thereof binds to phencyclidine with an affinity of kd.ltoreq.10 -9 M.
4. The antibody or antigen-binding fragment thereof of claim 2, wherein LFR1 of the antibody or antigen-binding fragment thereof has the amino acid sequence shown in SEQ ID No. 15.
5. The antibody or antigen-binding fragment thereof of claim 2, wherein LFR2 of the antibody or antigen-binding fragment thereof has the amino acid sequence shown in SEQ ID No. 16.
6. An anti-phencyclidine antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence structure of HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4 and a light chain variable region comprising the sequence structure of LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4, wherein the amino acid sequence of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 is the amino acid sequence of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3, LFR4 is the amino acid sequence of HFR1, HFR2, LCDR3, LFR4 of any one of claims 2 to 5.
7. An anti-phencyclidine antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID No. 19;
the amino acid sequence of the light chain variable region is shown in any one of SEQ ID NOs 20 to 23.
8. The antibody or antigen-binding fragment thereof of any one of claims 1 to 7, wherein the antibody or antigen-binding fragment thereof further comprises a constant region.
9. The antibody or antigen-binding fragment thereof of claim 8, wherein the constant regions comprise a heavy chain constant region and a light chain constant region.
10. The antibody or antigen-binding fragment thereof of claim 9, wherein the heavy chain constant region is selected from the group consisting of the heavy chain constant region of IgG1, igG2, igG3, igG4, igA, igM, igE, or IgD; the light chain constant region is selected from kappa-type or lambda-type light chain constant regions.
11. The antibody or antigen-binding fragment thereof of claim 9, wherein the constant region is of a species origin of bovine, equine, porcine, ovine, caprine, rat, mouse, canine, feline, rabbit, donkey, deer, mink, chicken, duck, goose, or human.
12. The antibody or antigen-binding fragment thereof of claim 9, wherein the constant region is of ovine species origin.
13. The antibody or antigen-binding fragment thereof of claim 9, wherein the heavy chain constant region sequence is as shown in SEQ ID No. 17 or has at least 80% homology thereto and the light chain constant region sequence is as shown in SEQ ID No. 18 or has at least 80% homology thereto.
14. The antibody or antigen-binding fragment thereof of any one of claims 1 to 7, wherein the antigen-binding fragment is selected from any one of F (ab ') 2, fab', fab, fv, and scFv of the antibody.
15. An anti-phencyclidine antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region as defined in any one of claims 6 to 7 and a heavy chain constant region as defined in any one of claims 9, 10 or 13; the light chain comprises the light chain variable region of any one of claims 6 to 7 and the light chain constant region of any one of claims 9, 10 or 13.
16. An anti-phencyclidine antibody comprises a heavy chain and a light chain, and is characterized in that the amino acid sequence of the heavy chain is shown as SEQ ID NO. 24; the amino acid sequence of the light chain is shown in any one of SEQ ID NOs 25 to 28.
17. An antibody conjugate comprising the antibody or antigen-binding fragment thereof of any one of claims 1 to 14 or the anti-phencyclidine antibody of claim 15 or 16; the antibody or antigen binding fragment thereof is labeled with a label.
18. The antibody conjugate of claim 17, wherein the label is selected from the group consisting of a fluorescent dye, an enzyme, a radioisotope, a chemiluminescent reagent, and a nanoparticle-based label.
19. The antibody conjugate of claim 18, wherein the fluorescent dye is selected from the group consisting of fluorescein-based dyes, rhodamine-based dyes, cy-based dyes, alexa-based dyes, and protein-based dyes.
20. The antibody conjugate of claim 18, wherein the enzyme is selected from horseradish peroxidase, alkaline phosphatase, beta-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and 6-phosphoglucose deoxygenase.
21. The antibody conjugate of claim 18, wherein the radioisotope is selected from the group consisting of 212Bi、131I、111In、90Y、186Re、211At、125I、188Re、153Sm、213Bi、32P、94mTc、99mTc、203Pb、67Ga、68Ga、43Sc、47Sc、110mIn、97Ru、62Cu、64Cu、67Cu、68Cu、86Y、88Y、121Sn、161Tb、166Ho、105Rh、177Lu、172Lu and 18 F.
22. The antibody conjugate of claim 18, wherein the chemiluminescent reagent is selected from the group consisting of luminol, luciferin, crustacean fluorescein, ruthenium bipyridine, acridinium esters, dioxane, lomustine and peroxyoxalate.
23. The antibody conjugate of claim 18, wherein the nanoparticle-based label is selected from the group consisting of a nanoparticle or a colloid.
24. The antibody conjugate of claim 23, wherein the nanoparticle-based label is selected from the group consisting of an organic nanoparticle, a magnetic nanoparticle, a quantum dot nanoparticle, and a rare earth complex nanoparticle.
25. The antibody conjugate of claim 23, wherein the colloid is selected from the group consisting of colloidal selenium, latex, colloidal metal, disperse dye, and dye-labeled microsphere.
26. The antibody conjugate of claim 25, wherein the colloidal metal is selected from the group consisting of colloidal gold and colloidal silver.
27. The antibody conjugate of claim 17, wherein the antibody or antigen binding fragment thereof is coated onto a solid phase.
28. The antibody conjugate of claim 27, wherein the solid phase is selected from the group consisting of a microsphere, a plate, and a membrane.
29. The antibody conjugate of claim 28, wherein the solid phase is selected from the group consisting of magnetic microspheres, plastic microparticles, microwell plates, glass, capillaries, nylon, and nitrocellulose membranes.
30. A reagent or kit for detecting phencyclidine, comprising the antibody or antigen-binding fragment thereof of any one of claims 1 to 14 or the anti-phencyclidine antibody of claim 15 or 16 or the antibody conjugate of any one of claims 17 to 29.
31. A nucleic acid encoding the antibody or antigen-binding fragment thereof of any one of claims 1 to 14 or the anti-phencyclidine antibody of claim 15 or 16.
32. A vector comprising the nucleic acid of claim 31.
33. A cell comprising the nucleic acid of claim 31 or the vector of claim 32.
34. A method of preparing the antibody or antigen-binding fragment thereof of any one of claims 1 to 14 or the anti-phencyclidine antibody of claim 15 or 16, comprising: culturing the cell of claim 33.
CN202210638701.2A 2022-06-08 2022-06-08 Anti-phencyclidine antibody, reagent for detecting phencyclidine and kit Active CN117229409B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210638701.2A CN117229409B (en) 2022-06-08 2022-06-08 Anti-phencyclidine antibody, reagent for detecting phencyclidine and kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210638701.2A CN117229409B (en) 2022-06-08 2022-06-08 Anti-phencyclidine antibody, reagent for detecting phencyclidine and kit

Publications (2)

Publication Number Publication Date
CN117229409A CN117229409A (en) 2023-12-15
CN117229409B true CN117229409B (en) 2024-04-23

Family

ID=89084913

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210638701.2A Active CN117229409B (en) 2022-06-08 2022-06-08 Anti-phencyclidine antibody, reagent for detecting phencyclidine and kit

Country Status (1)

Country Link
CN (1) CN117229409B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105669866A (en) * 2015-11-20 2016-06-15 艾博生物医药(杭州)有限公司 Hybridoma cell strain of phencyclidine (PCP) monoclonal antibody and preparation method thereof
CN114478764A (en) * 2020-11-12 2022-05-13 东莞市朋志生物科技有限公司 anti-AMH antibody, reagent and kit for detecting AMH

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242848A1 (en) * 2003-04-21 2004-12-02 Owens S. Michael Mouse/human chimeric anti-phencyclidine antibody and uses thereof
US20060073526A1 (en) * 2004-10-05 2006-04-06 Wako Pure Chemical Industries, Ltd Antibodies, assay method by using them and judgment method for pancreas cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105669866A (en) * 2015-11-20 2016-06-15 艾博生物医药(杭州)有限公司 Hybridoma cell strain of phencyclidine (PCP) monoclonal antibody and preparation method thereof
CN114478764A (en) * 2020-11-12 2022-05-13 东莞市朋志生物科技有限公司 anti-AMH antibody, reagent and kit for detecting AMH

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTI-PHENCYCLIDINE MONOCLONAL ANTIBODY BINDING CAPACITY IS NOT THE ONLY DETERMINANT OF EFFECTIVENESS, DISPROVING THE CONCEPT THAT ANTIBODY CAPACITY IS EASILY SURMOUNTED;Grzegorz Pitas等;Drug Metabolism and Disposition;20060630;第34卷(第6期);第906-912页 *
毒品苯环利啶(PCP)单克隆抗体的制备及鉴定;马涛等;云南大学学报;20031231(第S1期);第217-219页 *

Also Published As

Publication number Publication date
CN117229409A (en) 2023-12-15

Similar Documents

Publication Publication Date Title
WO2023078447A1 (en) Antibody against novel coronavirus and reagent and kit for testing novel coronavirus
CN116693676B (en) Anti-mycoplasma pneumoniae antibody, reagent for detecting mycoplasma pneumoniae and kit
CN117088982B (en) Anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine
CN116444657B (en) Antibodies against novel coronaviruses, reagents and kits for detecting novel coronaviruses
CN116836277B (en) Anti-estradiol antibody, reagent for detecting estradiol and kit
CN117229409B (en) Anti-phencyclidine antibody, reagent for detecting phencyclidine and kit
CN117487010A (en) Anti-tetraiodothyroxine antibody or functional fragment thereof, reagent for detecting tetraiodothyroxine and kit
CN117088984B (en) Anti-benzodiazepine antibody, and kit and reagent for detecting benzodiazepine
CN117285638B (en) Anti-buprenorphine antibodies, reagents and kits for the detection of buprenorphine
CN117285639B (en) Anti-ethyl glucuronide antibody, and reagent and kit for detecting ethyl glucuronide
CN117088975B (en) Anti-albumin antibody, reagent and kit for detecting albumin
CN117402239B (en) Anti-glycosylated hemoglobin antibody, reagent for detecting glycosylated hemoglobin and kit
CN117088983B (en) Anti-amphetamine antibodies, reagents and kits for detecting amphetamine
CN116836278B (en) Anti-progesterone antibody, kit for detecting progesterone
CN116693683B (en) Anti-testosterone antibody, reagent for detecting testosterone and kit
CN116836271B (en) Antibodies against type B streptococcus, reagents and kits for detecting type B streptococcus
CN116836279B (en) Anti-tetraiodothyroxine antibody, reagent and kit for detecting tetraiodothyroxine
CN116836273B (en) Anti-serum amyloid A antibody, reagent for detecting serum amyloid A and kit
CN116496401B (en) Anti-abnormal prothrombin antibody, reagent for detecting abnormal prothrombin and kit
CN116693677B (en) Antibodies against Chlamydia trachomatis, reagents and kits for detecting Chlamydia trachomatis
CN117327177B (en) Anti-adiponectin antibody, reagent for detecting adiponectin and kit
CN117229408A (en) Anti-barbital compound antibody, reagent for detecting barbital drugs and kit
CN116496394A (en) Antibodies against S100 protein, reagents and kits for detecting S100 protein
CN116640222A (en) Anti-2, 4-dinitrophenol antibody, conjugate comprising same, reagent, kit and application thereof
CN116854812A (en) Antibodies against Chlamydia trachomatis, reagents and kits for detecting Chlamydia trachomatis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant